(Q33676260)

28 July 2017

title

Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data (English)

1 reference

28 July 2017

2

Hans-Jürgen Möller

1 reference

Konstantinos N Fountoulakis

28 July 2017

series ordinal

1

object named as

Konstantinos N. Fountoulakis

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20800012

2 July 2024

language of work or name

1 reference

27 August 2010

1 reference

full work available at URL

28 July 2017

published in

The International Journal of Neuropsychopharmacology

1 reference

28 July 2017

volume

14

1 reference

28 July 2017

issue

3

1 reference

28 July 2017

page(s)

405-412

1 reference

Efficacy of cognitive-behavioural therapy and other psychological treatments for adult depression: meta-analytic study of publication bias

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000957

Psychotherapy for chronic major depression and dysthymia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000957

The antidepressant debate and the balanced placebo trial design: an ethical analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000957

Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000957

Committee for Medicinal Products for Human Use (CHMP) assessment on efficacy of antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000957

Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000957

Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000957

Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000957

Is the antidepressive effect of second-generation antidepressants a myth?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000957

A reevaluation of the exclusion criteria used in antidepressant efficacy trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000957

Efficacy of antidepressants in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000957

Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000957

Evidence-based medicine in psychopharmacotherapy: possibilities, problems and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000957

Principle standards and problems regarding proof of efficacy in clinical psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000957

Is evidence sufficient for evidence-based medicine?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000957

Antidepressants: controversies about their efficacy in depression, their effect on suicidality and their place in a complex psychiatric treatment approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000957

Isn't the efficacy of antidepressants clinically relevant? A critical comment on the results of the metaanalysis by Kirsch et al. 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000957

Do antidepressants work? A commentary on "Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration" by Kirsch et al.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000957

Brain blood flow changes in depressed patients treated with interpersonal psychotherapy or venlafaxine hydrochloride: preliminary findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000957

Clinical trials and the response rate illusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000957

Moving beyond depression: How full is the glass?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000957

Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000957

Placebo psychotherapy: synonym or oxymoron?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000957

Conditioning, expectancy, and the placebo effect: comment on Stewart-Williams and Podd (2004).

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000957

Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000957

Why antidepressants are not antidepressants: STEP-BD, STAR*D, and the return of neurotic depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000957

The ratio of means method as an alternative to mean differences for analyzing continuous outcome variables in meta-analysis: a simulation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000957

Consistency of the placebo effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000957

Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000957

7 January 2021

STAR*D: What Have We Learned?

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000957

7 January 2021

Modern Psychometrics in Clinimetrics: Impact on Clinical Trials of Antidepressants

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000957

7 January 2021

Meta-analysis of placebo-controlled trials with mirtazapine using the core items of the Hamilton Depression Scale as evidence of a pure antidepressive effect in the short-term treatment of major depression.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000957

7 January 2021

Antidepressants and the placebo response.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000957

7 January 2021

Are drug and placebo effects in depression additive?

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000957

7 January 2021

The placebo response: an experimental approach

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000957

7 January 2021

McGill Journal of Medicine

32

11

219

Kirsch

2008

1 reference

10.1017/S1461145710000957

DOI

https://api.crossref.org/works/10.1017/S1461145710000957

10.1017/S1461145710000957

2 July 2024

Identifiers

DOI

1 reference

28 July 2017

1 reference